Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.
Barclays (BARC) has received a new Buy rating, initiated by Bank of America Securities analyst, Rohith Chandrarajan.Stay Ahead of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
